Cystatin C to Creatinine Ratio and Measured GFR in Hospitalized Older Adults

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

In their editorial, Grubb et al examine differences between cystatin C– and creatinine-based estimated glomerular filtration rate (eGFRcys and eGFRcr, respectively). An eGFRcys:eGFRcr ratio <0.7 occurs in 0.3%-36% of patients (depending on the population) and is associated with worse health outcomes. The authors demonstrate how this ratio can be influenced both by nonrenal factors and by selective hypofiltration of cystatin C. However, most countries do not routinely measure cystatin C, limiting the application of this important distinction.
OriginalsprogEngelsk
TidsskriftAmerican Journal of Kidney Diseases
Vol/bind83
Udgave nummer6
Sider (fra-til)834-835
ISSN0272-6386
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
MBH is supported by the BRIDGE \u2013 Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation (Grant No. NNF20SA0064340). This funder had no role in the design or content of this letter or the decision to submit this letter. OA is a named inventor on patents covering suPAR owned by Copenhagen University Hospital Amager & Hvidovre, Hvidovre, Denmark, and licensed to ViroGates A/S. MBH and EI declare that they have no relevant financial interests. The OptiNAM study was performed as part of the Clinical Academic Group (ACUTE-CAG) for Recovery Capacity, nominated by the Greater Copenhagen Health Science Partners (GCHSP). We thank all patients and staff involved in the OptiNAM trial. Received October 16, 2023. Direct editorial input from an Associate Editor and a Deputy Editor. Accepted in revised form November 20, 2023.

Funding Information:
Support : MBH is supported by the BRIDGE \u2013 Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation (Grant No. NNF20SA0064340). This funder had no role in the design or content of this letter or the decision to submit this letter.

ID: 391744774